Cargando…
Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
The past two decades have witnessed major breakthroughs in developing compounds that target the chloride channel CFTR for the treatment of patients with cystic fibrosis. However, further improvement in affinity and efficacy for these CFTR modulators will require insights into the molecular interacti...
Autores principales: | Yeh, Han-I, Qiu, Liming, Sohma, Yoshiro, Conrath, Katja, Zou, Xiaoqin, Hwang, Tzyh-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605684/ https://www.ncbi.nlm.nih.gov/pubmed/31164398 http://dx.doi.org/10.1085/jgp.201912360 |
Ejemplares similares
-
A common mechanism for CFTR potentiators
por: Yeh, Han-I, et al.
Publicado: (2017) -
CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021) -
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
por: de Wilde, Gert, et al.
Publicado: (2019) -
On the mechanism of CFTR inhibition by a thiazolidinone derivative
por: Kopeikin, Zoia, et al.
Publicado: (2010) -
VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level
por: Cui, Guiying, et al.
Publicado: (2019)